Journal of International Oncology››2023,Vol. 50››Issue (1): 62-64.doi:10.3760/cma.j.cn371439-20220930-00013
Received:2022-09-30Revised:2022-11-25Online:2023-01-08Published:2023-03-16
"
"
"
| [1] | Abboud A, Masrouha K, Saliba M, et al. Extraskeletal ewing sarcoma: diagnosis, management and prognosis[J]. Oncol Lett, 2021, 21(5): 354. DOI: 10.3892/ol.2021.12615. doi:10.3892/ol.2021.12615pmid:33747211 |
| [2] | Riggi N, Suvà ML, Stamenkovic I. Ewing's sarcoma[J]. N Engl J Med, 2021, 384(2): 154-164. DOI: 10.1056/NEJMra2028910. doi:10.1056/NEJMra2028910 |
| [3] | Fan YH, Ma HX, Guo SP, et al. Application of anlotinib combined with neoadjuvant chemotherapy in primary EWS/PNET of lung: a case report[J]. Front Oncol, 2022, 12: 822469. DOI: 10.3389/fonc.2022.822469. doi:10.3389/fonc.2022.822469 |
| [4] | 朱玉春, 周伟, 张阳, 等. 肺骨外尤文肉瘤/原始神经外胚层肿瘤一例[J]. 临床放射学杂志, 2019, 38(6): 1151-1152. DOI: 10.13437/j.cnki.jcr.2019.06.052. doi:10.13437/j.cnki.jcr.2019.06.052 |
| [5] | 马文婷, 黎金葵, 雷军强. 1例胃原始神经外胚层肿瘤化疗前后CT影像学变化[J]. 国际肿瘤学杂志, 2017, 44(4): 319-320. DOI: 10.3760/cma.j.issn.1673-422X.2017.04.022. doi:10.3760/cma.j.issn.1673-422X.2017.04.022 |
| [6] | Zöllner SK, Amatruda JF, Bauer S, et al. Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives[J]. J Clin Med, 2021, 10(8): 1685. DOI: 10.3390/jcm10081685. doi:10.3390/jcm10081685 |
| [7] | 岳振营, 宋殿行, 王慧, 等. 肺原发性尤文肉瘤/原始神经外胚层肿瘤1例报道[J]. 诊断病理学杂志, 2017, 24(1): 52-54. DOI: 10.3969/j.issn.1007-8096.2017.01.014. doi:10.3969/j.issn.1007-8096.2017.01.014 |
| [8] | 韩秀鑫, 张超, 陶芳, 等. 尤文肉瘤的治疗研究进展[J]. 重庆医学, 2019, 48(7): 1191-1195. DOI: 10.3969/j.issn.1671-8348.2019.07.027. doi:10.3969/j.issn.1671-8348.2019.07.027 |
| [9] | 郭卫, 王臻, 郭征, 等. 尤文肉瘤肿瘤家族(ESFT)临床循证诊疗指南[J]. 中华骨与关节外科杂志, 2018, 11(4): 260-275. DOI: 10.3969/j.issn.2095-9958.2018.04.003. doi:10.3969/j.issn.2095-9958.2018.04.003 |
| [10] | Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, et al. Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival[J]. Clin Cancer Res, 2018, 24(19): 4865-4873. DOI: 10.1158/1078-0432.CCR-18-0202. doi:10.1158/1078-0432.CCR-18-0202pmid:29871905 |
| [11] | Whelan J, Le Deley MC, Dirksen U, et al. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and ewing-2008[J]. J Clin Oncol, 2018, 36(31): JCO2018782516. DOI: 10.1200/JCO.2018.78.2516. doi:10.1200/JCO.2018.78.2516 |
| [12] | Chang WI, Lin C, Liguori N, et al. Molecular targets for novel therapeutics in pediatric fusion-positive non-CNS solid tumors[J]. Front Pharmacol, 2021, 12: 747895. DOI: 10.3389/fphar.2021.747895. doi:10.3389/fphar.2021.747895 |
| [13] | Munster P, Mita M, Mahipal A, et al. First-in-human phase Ⅰ study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy[J]. Cancer Manag Res, 2019, 11: 10463-10476. DOI: 10.2147/CMAR.S208720. doi:10.2147/CMAR.S208720pmid:31853198 |
| [14] | Anderson PM, Bielack SS, Gorlick RG, et al. A phase Ⅱ study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma[J]. Pediatr Blood Cancer, 2016, 63(10): 1761-1770. DOI: 10.1002/pbc.26087. doi:10.1002/pbc.26087pmid:27362300 |
| [15] | Subbiah V, Braña I, Longhi A, et al. Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed Ewing sarcoma: results of a basket phase Ⅱ study[J]. Clin Cancer Res, 2022, 28(13): 2762-2770. DOI: 10.1158/1078-0432.CCR-22-0696. doi:10.1158/1078-0432.CCR-22-0696pmid:35486638 |
| [16] | Choy E, Butrynski JE, Harmon DC, et al. Phase Ⅱ study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy[J]. BMC Cancer, 2014, 14: 813. DOI: 10.1186/1471-2407-14-813. doi:10.1186/1471-2407-14-813 |
| [17] | Heisey DAR, Lochmann TL, Floros KV, et al. The Ewing family of tumors relies on BCL-2 and BCL-XL to escape PARP inhibitor toxicity[J]. Clin Cancer Res, 2019, 25(5): 1664-1675. DOI: 10.1158/1078-0432.CCR-18-0277. doi:10.1158/1078-0432.CCR-18-0277 |
| [18] | Italiano A, Mir O, Mathoulin-Pelissier S, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(3): 446-455. DOI: 10.1016/S1470-2045(19)30825-3. doi:10.1016/S1470-2045(19)30825-3 |
| [19] | Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial[J]. Lancet Oncol, 2017, 18(11): 1493-1501. DOI: 10.1016/S1470-2045(17)30624-1. doi:S1470-2045(17)30624-1pmid:28988646 |
| [20] | Guven DC, Kilickap S, Yildirim HC, et al. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: a case report[J]. J Oncol Pharm Pract, 2021, 27(5): 1281-1283. DOI: 10.1177/1078155220965677. doi:10.1177/1078155220965677pmid:33070764 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
